DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

An array of pharmaceutical pills with the company's logo on the bottle. Relay Therapeutics Inc. (NASDAQ ... “Buy” rating on the stock with a $17 target price. Barclays analysts said Eli ...

Among the innovators presenting at the symposium are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Agenus Inc. (NASDAQ: AGEN), Guardant Health, Inc. (NASDAQ: GH), Xilio Therapeutics ... trains ...

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Na ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report.

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, ...

JMP Securities restated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...